<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of anthrax</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of anthrax</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of anthrax</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth H Wilson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anthrax, usually caused by <em>Bacillus anthracis</em>, is an uncommon illness; the presentation can vary depending on the route of exposure. Consideration of the possibility of anthrax in patients with consistent clinical syndromes is important because of the potential for rapid disease progression and the public health implications.</p><p>The clinical manifestations and diagnosis of anthrax will be reviewed here. The pathogenesis, epidemiology, treatment, and prevention of anthrax are discussed separately. (See  <a class="medical medical_review" href="/d/html/5506.html" rel="external">"Microbiology, pathogenesis, and epidemiology of anthrax"</a> and  <a class="medical medical_review" href="/d/html/15309.html" rel="external">"Treatment of anthrax"</a> and  <a class="medical medical_review" href="/d/html/5535.html" rel="external">"Prevention of anthrax"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>There are four major anthrax syndromes: cutaneous anthrax, inhalation anthrax, gastrointestinal tract anthrax, and the more rare primary anthrax meningitis [<a href="#rid1">1-4</a>]. Anthrax has also been associated with injection drug use; in that setting, the clinical presentation is distinct from typical cutaneous anthrax.</p><p class="headingAnchor" id="H3"><span class="h2">Cutaneous</span><span class="headingEndMark"> — </span>Cutaneous anthrax is the most common form of the disease. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Route of infection</strong> – Naturally occurring cases of cutaneous anthrax develop after spores of <em>B. anthracis</em> are introduced subcutaneously, often as a result of contact with infected animals or animal products. Cuts or abrasions increase susceptibility to cutaneous infection [<a href="#rid5">5-7</a>]. Spores germinate and multiply, and the antiphagocytic capsule facilitates local spread. (See  <a class="medical medical_review" href="/d/html/5506.html" rel="external">"Microbiology, pathogenesis, and epidemiology of anthrax"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incubation period</strong> – The incubation period is usually 5 to 7 days with a range of 1 to 12 days [<a href="#rid8">8,9</a>]. However, during an anthrax outbreak in Sverdlovsk, Union of Soviet Socialist Republics, cutaneous cases developed up to 13 days following the aerosol release of spores [<a href="#rid10">10</a>]; an outbreak in Algeria was reported with a median incubation period of 19 days [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local features</strong> – Over 90 percent of cutaneous anthrax lesions occur in exposed areas such as the face, neck, arms, and hands. The disease begins as a small, painless, but often pruritic papule and quickly enlarges and develops a central vesicle or bulla, followed by erosion, leaving a painless necrotic ulcer with a black, depressed eschar (<a class="graphic graphic_picture graphicRef73444" href="/d/graphic/73444.html" rel="external">picture 1</a>) [<a href="#rid5">5</a>]. Extensive edema of the surrounding tissues, due to toxin release, is often present along with regional lymphadenopathy and lymphangitis (<a class="graphic graphic_picture graphicRef74874" href="/d/graphic/74874.html" rel="external">picture 2</a>). An eschar with extensive surrounding edema is highly suggestive of anthrax. Less often, <em>B. anthracis</em> can enter through the palpebral fissure, causing palpebral swelling and necrosis of the eyelids [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic symptoms and complications</strong> – Systemic symptoms, including fever, malaise, and headache can accompany the cutaneous lesion, although they do not occur in the majority of cases. In a systematic review that included 340 adults hospitalized with cutaneous anthrax, fever or chills were reported in 39 percent, fatigue and flu-like symptoms in 11 percent, and headache in 10 percent [<a href="#rid13">13</a>]; the proportion of children with such systemic symptoms was slightly lower. </p><p></p><p class="bulletIndent1">Complications include airway obstruction from head and neck involvement, sepsis syndrome, and meningitis. Overall, secondary meningitis has been reported in approximately 10 percent of patients hospitalized with cutaneous anthrax [<a href="#rid13">13</a>]. It is important to identify patients at risk for adverse outcomes. These include those with head and neck involvement, signs of sepsis, or signs of meningitis. (See  <a class="medical medical_review" href="/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1">Thus, fever or chills, hypotension, nausea or vomiting, altered mental status, headache, meningeal signs, other neurologic signs, papilledema, seizure, leukocytosis, bacteremia, coagulopathy, adenopathy and extensive edema are risk factors for meningitis or death [<a href="#rid14">14</a>]. Thoracic edema and anxiety also may be risk indicators.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality rate</strong> – Without appropriate therapy, mortality is quite high. However, where reasonably good health care is available, mortality is much lower. For example, in a cooperative study of treatment duration in Turkey, there were no deaths among 66 patient with uncomplicated cutaneous anthrax (no shock, sepsis, meningitis or pulmonary involvement) [<a href="#rid15">15</a>]. In a review of 85 cases from Eastern Turkey, there were two fatalities (2.4 percent), both in people with delayed admission and severe head and neck disease [<a href="#rid16">16</a>]. A review of 71 patients in Peru reported a mortality rate of 4.2 percent; all three deaths were in patients with meningoencephalitis [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Inhalation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Route of infection</strong> – Inhalation anthrax results from the inhalation of <em>B. anthracis</em> spore-containing particles. This may occur when anthrax spores are aerosolized while working with contaminated animal products such as wool, hair, or hides. It has also resulted from inhalation of weaponized and intentionally released spore preparations.</p><p></p><p class="bulletIndent1">Inhaled airborne particles &gt;5 microns in size are either physically trapped in the nasopharynx or cleared by the mucociliary escalator system. In comparison, inhaled particles &lt;5 microns in size can be deposited on alveolar ducts or alveoli [<a href="#rid8">8,18</a>]. <em>B. anthracis</em> spores are phagocytosed by alveolar macrophages and transported to mediastinal lymph nodes. There, they germinate, multiply, and release toxins, causing hemorrhagic necrosis of the thoracic lymph nodes draining the lungs, which results in a hemorrhagic mediastinitis and, in occasional cases, a necrotizing pneumonia [<a href="#rid19">19</a>]. The organisms then become bloodborne, causing bacteremia and, in many cases, meningitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incubation period</strong> – The median incubation period for inhalation anthrax is estimated to be seven to nine days [<a href="#rid13">13</a>]. However, both very short and very long incubation periods have been reported. In the 1979 outbreak in Sverdlovsk, the reported incubation period was as long as 43 days for fatal cases [<a href="#rid10">10</a>]. In contrast, information from a single case report suggests that the incubation period can be as short as one day [<a href="#rid20">20</a>]. This case report describes an office worker at a textile mill who developed inhalation anthrax within one day in 1961 following exposure in a grossly contaminated, dusty carding room in the mill; she previously rarely entered the mill.</p><p></p><p class="bulletIndent1">In primate studies, spores have been found in the lungs up to 100 days following exposure [<a href="#rid21">21</a>], and inhalation anthrax has developed up to 58 days following experimental aerosol exposure in primates receiving 30 days of postexposure antibiotics [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prodromal phase</strong> – The course of the disease is usually biphasic. Prodromal symptoms of inhalation anthrax are nonspecific and variable, complicating assessment and diagnosis [<a href="#rid1">1,23,24</a>]. Early symptoms, such as myalgia, fever, and malaise, are common and may mimic those of a viral respiratory infection. However, a variety of symptoms less suggestive of a viral infection may also be present, such as nausea, hemoptysis, dyspnea, odynophagia, or chest pain [<a href="#rid25">25</a>]. Prodromal symptoms last an average of four to five days. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fulminant phase</strong> – The fulminant phase is a catastrophic illness characterized by rapidly progressive respiratory symptoms, including severe dyspnea and hypoxemia, and shock [<a href="#rid6">6,20</a>]. This results in a very high mortality rate within days. </p><p></p><p class="bulletIndent1">As with any form of anthrax, hematogenous spread can result in lesions in other organ systems, including hemorrhagic meningitis and submucosal gastrointestinal lesions [<a href="#rid6">6,19</a>]. Approximately one-third to one-half of patients with inhalation anthrax develop secondary meningitis [<a href="#rid13">13,19</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging findings</strong> – Imaging studies can aid in establishing the diagnosis; almost all patients have some radiographic abnormality. Pleural effusion is common. Widening of the mediastinum, secondary to mediastinitis, is considered a classic finding in inhalation anthrax (<a class="graphic graphic_diagnosticimage graphicRef51574" href="/d/graphic/51574.html" rel="external">image 1</a>) [<a href="#rid26">26</a>]. In a systematic review of 90 adults hospitalized with inhalational anthrax, these findings were reported in 71 and 46 percent at presentation, respectively [<a href="#rid13">13</a>]. Other chest radiographic findings seen with inhalation anthrax include hilar abnormalities, pulmonary infiltrates, and consolidation. Imaging abnormalities, however, can often be subtle, particularly early in the course of illness [<a href="#rid27">27-29</a>]. (See <a class="local">'Distinction from common respiratory infections'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – Inhalation anthrax is usually fatal; among 71 cases in the world's literature from 1900 to 2005, excluding the 6 survivors during the 2001 bioterrorism event, the mortality rate was 92 percent [<a href="#rid25">25</a>]. It does not appear that modern intensive care has changed the outcome once the fulminant phase is reached. However, antibiotic therapy can be successful if initiated during the prodromal phase of the disease [<a href="#rid10">10,20,25,27</a>]. The challenge for the clinician is to appropriately treat patients during the prodromal stage, even though anthrax is a rare disease with a nonspecific and variable presentation. (See  <a class="medical medical_review" href="/d/html/15309.html" rel="external">"Treatment of anthrax"</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Gastrointestinal tract</span><span class="headingEndMark"> — </span>Gastrointestinal tract anthrax presents as one of two clinical forms, oropharyngeal or gastrointestinal anthrax. <em>B. anthracis</em> has been reported to infect all regions of the alimentary tract from the mouth to the ascending colon. The disease develops following the consumption of undercooked meat from animals infected with anthrax and tends to occur in family clusters or point-source outbreaks.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal form </strong>– Gastrointestinal involvement is likely to be more common than oropharyngeal disease, but its incidence is probably underestimated because it occurs mostly in medically underserved areas. The incubation period is estimated to be one to six days [<a href="#rid30">30</a>]. Following ingestion, the spores infect the alimentary tract epithelium. Necrotic ulcers, often similar to eschars on the skin, are surrounded by extensive edema of the infected intestinal segment and its adjacent mesentery; mesenteric lymph nodes may be enlarged and hemorrhagic [<a href="#rid31">31</a>]. Ulcerations can occur in the stomach, esophagus, and duodenum and may result in gastrointestinal hemorrhage. The case-fatality rate of gastrointestinal anthrax is estimated to range from 4 to 60 percent [<a href="#rid8">8,32</a>]. In a review of cases published between 1880 and 2018, the overall mortality was 74 percent [<a href="#rid13">13</a>]. However, this nonselective review likely included many patients who received no treatment. The low mortality rate estimate (4 percent) was derived from point-source outbreaks studied by public health officials in Uganda and Thailand, where large numbers of people ate uncooked meat from animals that died of anthrax. Most of the people who ate the uncooked meat became sick with gastroenteritis, which cleared with oral antibiotics. It may be that many of these patients did not have anthrax.</p><p></p><p class="bulletIndent1">One series described more than 100 patients in Lebanon with gastrointestinal anthrax; these patients received medical care [<a href="#rid31">31</a>]. The illness generally started with asthenia, headache, low-grade fevers, facial flushing, and conjunctival injection. This was followed by abdominal pain of variable intensity, nausea, vomiting, and, to a lesser extent, diarrhea. Typically, patients at this point had ascites and intravascular depletion. Later, the abdominal pain tended to become more severe, and patients had progression of ascites and hypotension. At surgery, segmental disease was usually found in the distal small bowel and/or proximal colon. Although they do not cite the survival rate, most patients (even those who required surgery) survived.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oropharyngeal form</strong> – The oropharyngeal form of anthrax is less frequent and also develops following consumption of undercooked, contaminated meat. Edematous lesions develop, which progress over one to two weeks to necrotic ulcers covered with a pseudomembrane. Edema and painful swelling may develop in the oropharynx and neck, accompanied by cervical lymphadenopathy, pharyngitis, and fever [<a href="#rid30">30,32,33</a>]. The mortality from this disease can be substantial even with parenteral antibiotic treatment [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Meningitis</span><span class="headingEndMark"> — </span>Primary meningitis (meningitis as the presenting syndrome without clear route of exposure) is a rare form of anthrax. In contrast, secondary meningitis through bacteremic spread occurs in about a third of patients with other forms of systemic anthrax and has been associated with cutaneous, inhalation, and gastrointestinal cases [<a href="#rid4">4</a>]. </p><p>Clinical features include fever, headache, and meningeal signs [<a href="#rid13">13</a>]. Delirium or coma follows quickly after presentation. Refractory seizures, cranial nerve palsies, and myoclonus have been reported [<a href="#rid2">2,34</a>]. </p><p>Anthrax meningitis is frequently associated with intracranial hemorrhage [<a href="#rid4">4</a>]. This is typically identified by imaging (computed tomography or magnetic resonance imaging) or lumbar puncture. Cerebrospinal fluid (CSF) analysis reveals an elevated protein (70 percent), low glucose (37 percent), and a positive Gram stain (77 percent) and culture (81 percent) (<a class="graphic graphic_picture graphicRef56832" href="/d/graphic/56832.html" rel="external">picture 3</a>) [<a href="#rid34">34</a>]. Parenchymal brain hemorrhage may be so severe that a grossly bloody lumbar puncture may be confused with a traumatic tap. A review of 44 well-documented cases found that 75 percent of patients died within 24 hours of presentation, with an overall survival of only 6 percent [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H365640039"><span class="h2">Injection anthrax</span><span class="headingEndMark"> — </span>Anthrax has been associated with injection drug use [<a href="#rid35">35</a>]. Although the injection site is usually the route of infection, the clinical presentation is distinct from the typical syndrome of cutaneous anthrax. Skin and soft tissue findings include substantial edema and swelling at injection site, blistering and skin necrosis, and lack of the classic eschar [<a href="#rid36">36</a>]. </p><p>Systemic symptoms are also commonly reported. In a systematic review that included 59 adults hospitalized with anthrax associated with injection drug use, fever or chills were reported in 49 percent, fatigue and flu-like symptoms in 27 percent, and diaphoresis in 20 percent [<a href="#rid13">13</a>]. In another review, nonspecific gastrointestinal symptoms such as nausea, vomiting, and abdominal pain were reported in over half of confirmed cases and various neurologic symptoms in approximately one-third [<a href="#rid36">36</a>]. </p><p>Among reported cases of adults hospitalized with injection-associated anthrax between 1960 and 2018, the mortality rate was 33 percent [<a href="#rid13">13</a>].</p><p>The epidemiology of injection-related anthrax outbreaks is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5506.html" rel="external">"Microbiology, pathogenesis, and epidemiology of anthrax", section on 'Injection anthrax'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H1507245216"><span class="h2">Contacting public health officials</span><span class="headingEndMark"> — </span>The possibility of anthrax should be suspected in patients with a consistent clinical syndrome and consistent epidemiology (eg, exposure to animals or animal hides or clusters of similar cases that could portend a bioterrorism event). In the United States, when anthrax is suspected, clinicians should contact their local or state health department immediately to notify them and review specimen collection and submission guidelines. Non-culture testing is typically performed at a reference laboratory. (See <a class="local">'Specimen handling and transport to a reference lab'</a> below.)</p><p class="headingAnchor" id="H3017331624"><span class="h2">Evaluation by clinical syndrome</span></p><p class="headingAnchor" id="H12"><span class="h3">Inhalation anthrax</span></p><p class="headingAnchor" id="H13"><span class="h4">Distinction from common respiratory infections</span><span class="headingEndMark"> — </span>It is important to distinguish potential inhalation anthrax cases from more common disorders such as community-acquired pneumonia (CAP), influenza, and influenza-like illnesses (ILI). As mentioned above, this may be difficult. If the patient has influenza, respiratory syncytial virus, or coronavirus disease 2019 (COVID-19), a positive test can allay concerns about anthrax. The epidemiologic setting is important, especially with regards to occupational history and hobbies (eg, drum maker) or if there is an association with other cases, as in the occurrence of a suspected bioterrorism event.</p><p>The bioterrorism event of 2001 illustrated the importance of screening for inhalation anthrax because the window of opportunity for successful treatment is narrow once symptoms appear. Clinical signs more frequently associated with inhalation anthrax compared with CAP or ILI included shortness of breath, nausea, vomiting, altered mental status, pallor or cyanosis, and hematocrit &gt;45 percent [<a href="#rid26">26,37</a>]. In contrast, symptoms more suggestive of an ILI included rhinorrhea and sore throat [<a href="#rid37">37</a>]. Unexplained mediastinal widening on chest radiography in a compatible clinical setting should raise the possibility of inhalation anthrax. Other radiographic findings are probably not specific enough to be helpful in an unsuspected sporadic case, but such findings can be helpful in an outbreak situation or if there was a known risk of exposure. In the 2001 outbreak, pleural effusion was more common in patients with inhalation anthrax than in those with CAP [<a href="#rid38">38</a>]. Although chest radiographs are almost always abnormal in patients with inhalation anthrax, these findings are sometimes subtle, and they may be initially overlooked. Thus, the diagnosis of inhalation anthrax cannot be ruled out even if a chest radiograph is interpreted as normal early in the course of illness.</p><p class="headingAnchor" id="H14"><span class="h4">Approach to testing</span><span class="headingEndMark"> — </span>Diagnostic testing should be performed on specimens from patients being evaluated for inhalation anthrax, including patients with a known exposure or high risk of exposure, patients with a clear epidemiologic link presenting with symptoms of inhalation anthrax, and patients with a clinical presentation suggestive of anthrax in the absence of an alternate diagnosis.</p><p>The following diagnostic testing is recommended for patients with suspected inhalation anthrax (<a class="graphic graphic_table graphicRef141224" href="/d/graphic/141224.html" rel="external">table 1</a>) [<a href="#rid39">39</a>]. Specimens submitted for culture should ideally be collected prior to antimicrobial therapy. Non-culture testing is typically performed at a reference laboratory. (See <a class="local">'Specimen handling and transport to a reference lab'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Blood for routine culture and for polymerase chain reaction (PCR) testing </p><p class="bulletIndent1"><span class="glyph">●</span>Acute and convalescent serum samples for serologic testing</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma to test for anthrax lethal factor toxin (this can also be performed on acute serum)</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural fluid, if present, for Gram stain, culture, PCR, and testing for anthrax lethal factor toxin</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural and/or bronchial biopsies for PCR and immunohistochemistry, if other tests are negative</p><p></p><p>Evaluation of cerebrospinal fluid (CSF) is also warranted in patients with systemic anthrax (including inhalational anthrax). (See <a class="local">'Meningitis'</a> below.)</p><p class="headingAnchor" id="H15"><span class="h3">Cutaneous anthrax</span><span class="headingEndMark"> — </span>The possibility of cutaneous anthrax should be suspected in a patient with a cutaneous eschar (<a class="graphic graphic_picture graphicRef73444" href="/d/graphic/73444.html" rel="external">picture 1</a>), especially with extensive edema disproportionate to the lesion size, and potential exposure (eg, to animals or animal hides or in the setting of clusters of similar cases). Gram-positive rods and few polymorphonuclear leukocytes on Gram stain are strongly suggestive of cutaneous anthrax (<a class="graphic graphic_picture graphicRef58039" href="/d/graphic/58039.html" rel="external">picture 4</a>). </p><p>The following diagnostic testing is recommended for patients with suspected cutaneous anthrax (<a class="graphic graphic_table graphicRef141224" href="/d/graphic/141224.html" rel="external">table 1</a>) [<a href="#rid39">39</a>]. Specimens submitted for culture should ideally be collected prior to antimicrobial therapy. Non-culture testing is typically performed at a reference laboratory. (See <a class="local">'Specimen handling and transport to a reference lab'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Lesion specimens: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For vesicular lesions, two swabs of vesicular fluid from an unopened vesicle, one for Gram stain and culture, the second for PCR testing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For eschars, the edge should be lifted and two swabs rotated underneath and submitted, one for Gram stain and culture, the second for PCR testing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For ulcers, the base of the lesion should be sampled with two saline-moistened swabs and submitted, one for Gram stain and culture, the second for PCR testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biopsy – In addition, a full-thickness punch biopsy of a papule or vesicle including adjacent skin from all patients should be submitted in 10 percent formalin for histopathology and immunohistochemistry. In patients not receiving antibiotic therapy or on therapy for &lt;24 hours, a second biopsy specimen should be submitted for Gram stain, culture, and PCR testing [<a href="#rid9">9,40,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute and convalescent serum samples for serologic testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma to test for anthrax lethal factor toxin (this can also be performed on acute serum).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with evidence of systemic illness (eg, fever, tachycardia, hypotension), blood for culture and PCR testing.</p><p></p><p>Evaluation of CSF is also warranted in patients with signs of secondary meningitis or other features of systemic infection (eg, sepsis). (See <a class="local">'Meningitis'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h3">Gastrointestinal tract anthrax</span><span class="headingEndMark"> — </span>Information regarding the reliability of diagnostic testing in gastrointestinal tract anthrax is limited. The following diagnostic testing is recommended for patients with suspected gastrointestinal tract anthrax (<a class="graphic graphic_table graphicRef141224" href="/d/graphic/141224.html" rel="external">table 1</a>) [<a href="#rid39">39</a>]. Specimens submitted for culture should ideally be collected prior to antimicrobial therapy. Non-culture testing is typically performed at a reference laboratory. (See <a class="local">'Specimen handling and transport to a reference lab'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Blood for culture and PCR testing</p><p class="bulletIndent1"><span class="glyph">●</span>Acute and convalescent serum samples for serologic testing</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma to test for anthrax lethal factor toxin (this can also be performed on acute serum)</p><p class="bulletIndent1"><span class="glyph">●</span>Ascites fluid for Gram stain, culture, PCR testing, and testing for anthrax lethal factor toxin</p><p class="bulletIndent1"><span class="glyph">●</span>Rectal swab for Gram stain, culture, and PCR testing</p><p class="bulletIndent1"><span class="glyph">●</span>Oropharyngeal lesion, if present, for Gram stain, culture, and PCR testing</p><p></p><p>If the patient undergoes surgery, affected tissue can be obtained for Gram stain, culture, and PCR testing; immunohistochemistry can be performed on formalinized tissue.</p><p>Evaluation of CSF is also warranted in patients with systemic anthrax (including gastrointestinal anthrax). (See <a class="local">'Meningitis'</a> below.)</p><p>Culture from stool frequently does not yield <em>B. anthracis</em> [<a href="#rid30">30</a>], but Gram stain or culture of oropharyngeal lesions or ascitic fluid may be positive (<a class="graphic graphic_picture graphicRef58039" href="/d/graphic/58039.html" rel="external">picture 4</a>) [<a href="#rid31">31</a>]. Blood cultures may also be positive when collected prior to initiating antimicrobial therapy [<a href="#rid31">31</a>]. Serologic testing for antibodies against protective antigen were positive in 7 of 10 oropharyngeal anthrax cases tested [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H3312663705"><span class="h3">Meningitis</span><span class="headingEndMark"> — </span>All patients with systemic anthrax should undergo evaluation for meningitis. In particular, the possibility of anthrax meningitis should be suspected in any patient with known or suspected anthrax at another clinical site who has severe nausea or vomiting, altered mental status, headache, meningeal signs, other neurologic signs, papilledema, or seizure. It should also be suspected in patients not known to have anthrax and who have undiagnosed hemorrhagic meningitis.</p><p>In addition to the blood, serum, and plasma testing recommended for all patients with systemic anthrax (see <a class="local">'Approach to testing'</a> above), diagnostic testing for patients with suspected anthrax meningitis includes (<a class="graphic graphic_table graphicRef141224" href="/d/graphic/141224.html" rel="external">table 1</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>CSF for culture and PCR testing</p><p></p><p>In a mass-casualty situation, especially if resources become limited preventing lumbar puncture and CSF testing on all patients, it may be necessary to make the presumptive diagnosis of meningitis on signs and symptoms alone [<a href="#rid42">42,43</a>]. </p><p class="headingAnchor" id="H2000690485"><span class="h2">Specimen handling and transport to a reference lab</span><span class="headingEndMark"> — </span>Details of specimen handling and transport should be established through consultation with the local microbiology laboratory, the state health department, and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Femergency.cdc.gov%2Flrn%2Fcontact.asp&amp;token=%2FXpciKoGXD%2FNBcI56myByC78r1g42d9%2BGqNDkCc%2BGMc5%2B5Z757T%2FLJgfnU89qJsPPfWfjxgIYOewSg6FZqKDFQ%3D%3D&amp;TOPIC_ID=5533" target="_blank">Laboratory Response Network</a> (LRN) reference laboratory. In general, the guidelines below should apply:</p><p class="bulletIndent1"><span class="glyph">●</span>Specimens of stool, sputum, pleural fluid, CSF, and blood stored at 2 to 8°C</p><p class="bulletIndent1"><span class="glyph">●</span>Swabs at room temperature</p><p class="bulletIndent1"><span class="glyph">●</span>Fresh tissue samples frozen</p><p class="bulletIndent1"><span class="glyph">●</span>Formalin-fixed specimens at room temperature</p><p></p><p>Blood specimens for PCR testing should optimally be collected in tubes containing ethylenediaminetetraacetic acid (EDTA) or citrate as anticoagulant and not heparin. Isolates of <em>Bacillus</em> can be transported on most nonselective laboratory media at room temperature. Specific information on specimen types, volumes, and transport conditions is summarized in the table (<a class="graphic graphic_table graphicRef65814" href="/d/graphic/65814.html" rel="external">table 2</a>).</p><p>The LRN was established in 1999 by the Centers for Disease Control and Prevention (CDC), the Association of Public Health Laboratories (APHL), the Federal Bureau of Investigation (FBI), and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for the rapid identification of selected agents, including <em>B. anthracis</em> [<a href="#rid44">44</a>]. The LRN is part of a linked hierarchy of sentinel, reference, and national-level laboratories. There are LRN reference laboratories (generally state public health laboratories) in all 50 states. These laboratories can be accessed through the local health departments.</p><p class="headingAnchor" id="H2421366595"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of anthrax is made by the growth of <em>B. anthracis</em> on culture of a clinical specimen. Isolation of a <em>B. cereus</em> group organism from a patient with a compatible clinical syndrome and epidemiology should also be considered anthrax until proven otherwise. Depending on the syndrome, blood, skin lesion specimens, pleural fluid, cerebrospinal fluid (CSF), rectal swab, ascitic fluid or tissue can be cultured. The diagnosis is also supported by a positive polymerase chain reaction (PCR) on one of these specimens, positive serologic testing, or detection of lethal toxin in a patient with a compatible clinical syndrome; these non-culture tests are generally available only through reference laboratories. Testing for anthrax is discussed elsewhere. (See <a class="local">'Diagnostic evaluation'</a> above.) </p><p>Clinicians who suspect anthrax should communicate closely with their clinical laboratory to ensure appropriate microbiologic workup of any <em>Bacillus</em> isolate and to send the isolate to a reference laboratory for definitive identification. In the United States, this should be accomplished by immediately notifying the state health department and, with their assistance, the appropriate Laboratory Response Network (LRN) reference laboratory [<a href="#rid44">44</a>]. (See <a class="local">'Specimen handling and transport to a reference lab'</a> above.)</p><p><em>B. anthracis </em>grows rapidly on routine culture media. However, several issues pose challenges to the microbiologic diagnosis of anthrax in the clinical laboratory. Clinical laboratories may not routinely work up an isolated <em>Bacillus</em> species since these organisms most commonly reflect contamination. Furthermore, <em>B. anthracis </em>belongs to the <em>Bacillus cereus</em> group, and species within this group are so closely related that routine testing does not reliably distinguish them [<a href="#rid45">45</a>]. Additionally, rare strains of <em>B. cereus</em> can harbor virulence plasmids and cause syndromes indistinguishable from anthrax [<a href="#rid46">46-49</a>]. </p><p>Finally, the  (MALDI-TOF MS) systems that most laboratories use to identify microbes may not specifically identify <em>B. anthracis</em>. In the United States, two systems are the most widely used. The Biomerieux system classifies <em>B. anthracis</em> as “<em>B. cereus </em>group.” The Bruker system uses two panels, neither of which identifies <em>B. anthracis</em>. Although Bruker offers a supplemental panel that can identify <em>B. anthracis</em>, it does not come standard with the system.</p><p>Standard susceptibility testing is still relied upon as for other pathogens [<a href="#rid50">50</a>], and susceptibility testing should be carried out while the organism is being worked up by a reference lab. </p><p class="headingAnchor" id="H1182704626"><span class="h1">OTHER EVALUATION</span><span class="headingEndMark"> — </span>For patients with suspected or documented systemic anthrax, the initial evaluation also focuses on potential complications of infection. This work-up is detailed in the table (<a class="graphic graphic_table graphicRef119773" href="/d/graphic/119773.html" rel="external">table 3</a>) and includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Routine laboratory testing: Complete blood count, electrolytes, kidney function tests, liver enzymes, and coagulation tests</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram</p><p class="bulletIndent1"><span class="glyph">●</span>Chest imaging </p><p class="bulletIndent1"><span class="glyph">●</span>Lumbar puncture for cell count, glucose, total protein, Gram stain, culture, and polymerase chain reaction (PCR) testing</p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiogram </p><p></p><p>Ongoing monitoring for patients with systemic anthrax is also warranted. This is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/15309.html" rel="external">"Treatment of anthrax", section on 'Monitoring'</a>.)</p><p class="headingAnchor" id="H924230100"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109936.html" rel="external">"Society guideline links: Anthrax"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical syndromes</strong> – There are four major anthrax syndromes: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cutaneous anthrax</strong> – This is the most common form of anthrax. It begins as a small, painless, but often pruritic papule that quickly enlarges and develops a central vesicle or bulla, followed by erosion, resulting in a necrotic ulcer with a black, depressed eschar (<a class="graphic graphic_picture graphicRef73444" href="/d/graphic/73444.html" rel="external">picture 1</a>). There is often extensive surrounding edema, regional lymphadenopathy, and lymphangitis (<a class="graphic graphic_picture graphicRef74874" href="/d/graphic/74874.html" rel="external">picture 2</a>). (See <a class="local">'Cutaneous'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inhalation anthrax</strong> – Early clinical symptoms are nonspecific and include myalgia, fever, and malaise, which can mimic a viral respiratory infection. After an average of four to five days, patients become dramatically sicker with progressive respiratory symptoms, including severe dyspnea, hypoxemia, and shock. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal tract anthrax</strong> – This is characterized by necrotic ulcers with surrounding edema in the mucosa of the gastrointestinal tract, which can result in hemorrhage. Patients also present with abdominal pain, nausea, and vomiting. An oropharyngeal form involves lesions in the mouth and throat, with painful edema in the neck, pharyngitis, and cervical lymphadenopathy. (See <a class="local">'Gastrointestinal tract'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anthrax meningitis</strong> – Meningitis rarely occurs as the presenting syndrome but occurs in about a third of patients with systemic anthrax. It is associated with parenchymal brain hemorrhage that can result in grossly bloody cerebrospinal fluid (CSF) and rapid progression to delirium or coma. (See <a class="local">'Meningitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The possibility of anthrax should be suspected in patients with a consistent clinical syndrome (as above) and consistent epidemiology (eg, exposure to animals or animal hides or clusters of similar cases that could portend bioterrorism event). In the United States, when anthrax is suspected, clinicians should contact their local or state health department immediately to notify them and review specimen collection and submission. Diagnostic testing includes culture and polymerase chain reaction (PCR) testing of blood and specimens from affected clinical sites, acute and convalescent serologic testing, and testing for lethal factor toxin on plasma (<a class="graphic graphic_table graphicRef141224" href="/d/graphic/141224.html" rel="external">table 1</a>). All patients with systemic anthrax (ie, all forms of anthrax other than limited cutaneous disease) should be evaluated for meningitis. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of anthrax is made by the growth of <em>B. anthracis</em> on culture of a clinical specimen. Isolation of a <em>B. cereus</em> group organism from a patient with a compatible clinical syndrome and epidemiology should also be considered anthrax until proven otherwise. The diagnosis is also supported by a positive PCR from clinical specimens, detection of lethal toxin in blood or body fluid, or positive serologic testing. (See <a class="local">'Diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">LaForce FM. Anthrax. Clin Infect Dis 1994; 19:1009.</a></li><li><a class="nounderline abstract_t">Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341:815.</a></li><li><a class="nounderline abstract_t">Swartz MN. Recognition and management of anthrax--an update. N Engl J Med 2001; 345:1621.</a></li><li><a class="nounderline abstract_t">Caffes N, Hendricks K, Bradley JS, et al. Anthrax Meningoencephalitis and Intracranial Hemorrhage. Clin Infect Dis 2022; 75:S451.</a></li><li><a class="nounderline abstract_t">Wenner KA, Kenner JR. Anthrax. Dermatol Clin 2004; 22:247.</a></li><li><a class="nounderline abstract_t">Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287:2236.</a></li><li><a class="nounderline abstract_t">Pile JC, Malone JD, Eitzen EM, Friedlander AM. Anthrax as a potential biological warfare agent. Arch Intern Med 1998; 158:429.</a></li><li class="breakAll">Brachman P, Kaufmann A. Anthrax. In: Bacterial infections of Humans: Epidemiology and Control, 3rd ed, Evans A, Brachman P (Eds), Plenum Publishing, New York 1998. p.95.</li><li><a class="nounderline abstract_t">Carucci JA, McGovern TW, Norton SA, et al. Cutaneous anthrax management algorithm. J Am Acad Dermatol 2002; 47:766.</a></li><li><a class="nounderline abstract_t">Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266:1202.</a></li><li><a class="nounderline abstract_t">Abdenour D, Larouze B, Dalichaouche M, Aouati M. Familial occurrence of anthrax in Eastern Algeria. J Infect Dis 1987; 155:1083.</a></li><li><a class="nounderline abstract_t">Eshraghi B, Zarrin Y, Fazel M. Palpebral anthrax, a rare though important condition in villagers: A case report and literature review. Int J Infect Dis 2020; 99:260.</a></li><li><a class="nounderline abstract_t">Hendricks K, Person MK, Bradley JS, et al. Clinical Features of Patients Hospitalized for All Routes of Anthrax, 1880-2018: A Systematic Review. Clin Infect Dis 2022; 75:S341.</a></li><li><a class="nounderline abstract_t">Thompson JM, Cook R, Person MK, et al. Risk Factors for Death or Meningitis in Adults Hospitalized for Cutaneous Anthrax, 1950-2018: A Systematic Review. Clin Infect Dis 2022; 75:S459.</a></li><li><a class="nounderline abstract_t">Kayabas U, Karahocagil MK, Ozkurt Z, et al. Naturally occurring cutaneous anthrax: antibiotic treatment and outcome. Chemotherapy 2012; 58:34.</a></li><li><a class="nounderline abstract_t">Karahocagil MK, Akdeniz N, Akdeniz H, et al. Cutaneous anthrax in Eastern Turkey: a review of 85 cases. Clin Exp Dermatol 2008; 33:406.</a></li><li><a class="nounderline abstract_t">Maguiña C, Flores Del Pozo J, Terashima A, et al. Cutaneous anthrax in Lima, Peru: retrospective analysis of 71 cases, including four with a meningoencephalic complication. Rev Inst Med Trop Sao Paulo 2005; 47:25.</a></li><li><a class="nounderline abstract_t">DRUETT HA, HENDERSON DW, PACKMAN L, PEACOCK S. Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. J Hyg (Lond) 1953; 51:359.</a></li><li><a class="nounderline abstract_t">Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993; 90:2291.</a></li><li><a class="nounderline abstract_t">Brachman PS. Inhalation anthrax. Ann N Y Acad Sci 1980; 353:83.</a></li><li><a class="nounderline abstract_t">HENDERSON DW, PEACOCK S, BELTON FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 1956; 54:28.</a></li><li><a class="nounderline abstract_t">Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167:1239.</a></li><li><a class="nounderline abstract_t">PLOTKIN SA, BRACHMAN PS, UTELL M, et al. An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features. Am J Med 1960; 29:992.</a></li><li><a class="nounderline abstract_t">Borio L, Frank D, Mani V, et al. Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA 2001; 286:2554.</a></li><li><a class="nounderline abstract_t">Holty JE, Bravata DM, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270.</a></li><li><a class="nounderline abstract_t">Kyriacou DN, Stein AC, Yarnold PR, et al. Clinical predictors of bioterrorism-related inhalational anthrax. Lancet 2004; 364:449.</a></li><li><a class="nounderline abstract_t">Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:941.</a></li><li><a class="nounderline abstract_t">Barakat LA, Quentzel HL, Jernigan JA, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002; 287:863.</a></li><li><a class="nounderline abstract_t">Beatty ME, Ashford DA, Griffin PM, et al. Gastrointestinal anthrax: review of the literature. Arch Intern Med 2003; 163:2527.</a></li><li><a class="nounderline abstract_t">Kanafani ZA, Ghossain A, Sharara AI, et al. Endemic gastrointestinal anthrax in 1960s Lebanon: clinical manifestations and surgical findings. Emerg Infect Dis 2003; 9:520.</a></li><li><a class="nounderline abstract_t">Sirisanthana T, Brown AE. Anthrax of the gastrointestinal tract. Emerg Infect Dis 2002; 8:649.</a></li><li><a class="nounderline abstract_t">Sirisanthana T, Navachareon N, Tharavichitkul P, et al. Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis. Am J Trop Med Hyg 1984; 33:144.</a></li><li><a class="nounderline abstract_t">Lanska DJ. Anthrax meningoencephalitis. Neurology 2002; 59:327.</a></li><li class="breakAll">Health Protection Scotland. An outbreak of anthrax among drug users in Scotland, December 2009 to December 2010. A report on behalf of the National Anthrax Outbreak Control Team. http://www.documents.hps.scot.nhs.uk/giz/anthrax-outbreak/anthrax-outbreak-report-2011-12.pdf (Accessed on January 16, 2012).</li><li><a class="nounderline abstract_t">Berger T, Kassirer M, Aran AA. Injectional anthrax - new presentation of an old disease. Euro Surveill 2014; 19.</a></li><li><a class="nounderline abstract_t">Hupert N, Bearman GM, Mushlin AI, Callahan MA. Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med 2003; 139:337.</a></li><li><a class="nounderline abstract_t">Sirisanthana T, Nelson KE, Ezzell JW, Abshire TG. Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand. Am J Trop Med Hyg 1988; 39:575.</a></li><li class="breakAll">CDC. Recommended Specimens for Anthrax Testing by Clinical Presentation. https://www.cdc.gov/anthrax/lab-testing/recommended-specimens/clinical-presentation.html (Accessed on April 07, 2023).</li><li><a class="nounderline abstract_t">Guarner J, Jernigan JA, Shieh WJ, et al. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 2003; 163:701.</a></li><li><a class="nounderline abstract_t">Shieh WJ, Guarner J, Paddock C, et al. The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax. Am J Pathol 2003; 163:1901.</a></li><li><a class="nounderline abstract_t">Bower WA, Hendricks K, Pillai S, et al. Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident. MMWR Recomm Rep 2015; 64:1.</a></li><li><a class="nounderline abstract_t">Katharios-Lanwermeyer S, Holty JE, Person M, et al. Identifying Meningitis During an Anthrax Mass Casualty Incident: Systematic Review of Systemic Anthrax Since 1880. Clin Infect Dis 2016; 62:1537.</a></li><li><a class="nounderline abstract_t">Morse SA, Kellogg RB, Perry S, et al. Detecting Biothreat Agents: the Laboratory Response Network. ASM News 2003; 69:433.</a></li><li><a class="nounderline abstract_t">Carroll LM, Cheng RA, Wiedmann M, Kovac J. Keeping up with the Bacillus cereus group: taxonomy through the genomics era and beyond. Crit Rev Food Sci Nutr 2022; 62:7677.</a></li><li><a class="nounderline abstract_t">Baldwin VM. You Can't B. cereus - A Review of Bacillus cereus Strains That Cause Anthrax-Like Disease. Front Microbiol 2020; 11:1731.</a></li><li class="breakAll">American Society for Microbiology. Sentinel Level Clinical Microbiology Guidelines for Suspected Agents of Bioterrorism and Emerging Infectious Diseases: Bacillus anthracis and Bacillus cereus biovar anthracis
. 2017. https://asm.org/ASM/media/Policy-and-Advocacy/LRN/Sentinel%20Files/AnthraxLRN-Aug2017.pdf (Accessed on March 12, 2021).</li><li><a class="nounderline abstract_t">Hendricks K, Martines RB, Bielamowicz H, et al. Welder's Anthrax: A Tale of 2 Cases. Clin Infect Dis 2022; 75:S354.</a></li><li><a class="nounderline abstract_t">Dawson P, Schrodt CA, Feldmann K, et al. Notes from the Field: Fatal Anthrax Pneumonia in Welders and Other Metalworkers Caused by Bacillus cereus Group Bacteria Containing Anthrax Toxin Genes - U.S. Gulf Coast States, 1994-2020. MMWR Morb Mortal Wkly Rep 2021; 70:1453.</a></li><li><a class="nounderline abstract_t">Maxson T, Kongphet-Tran T, Mongkolrattanothai T, et al. Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947-2019. Clin Infect Dis 2022; 75:S373.</a></li></ol></div><div id="topicVersionRevision">Topic 5533 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7888525" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10477781" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704686" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recognition and management of anthrax--an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36251558" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Anthrax Meningoencephalitis and Intracranial Hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15207306" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11980524" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anthrax as a biological weapon, 2002: updated recommendations for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9508220" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anthrax as a potential biological warfare agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9508220" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Anthrax as a potential biological warfare agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399771" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cutaneous anthrax management algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7973702" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Sverdlovsk anthrax outbreak of 1979.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3559284" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Familial occurrence of anthrax in Eastern Algeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32758692" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Palpebral anthrax, a rare though important condition in villagers: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36251560" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical Features of Patients Hospitalized for All Routes of Anthrax, 1880-2018: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36251551" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk Factors for Death or Meningitis in Adults Hospitalized for Cutaneous Anthrax, 1950-2018: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343361" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Naturally occurring cutaneous anthrax: antibiotic treatment and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477006" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cutaneous anthrax in Eastern Turkey: a review of 85 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729471" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cutaneous anthrax in Lima, Peru: retrospective analysis of 71 cases, including four with a meningoencephalic complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13096744" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8460135" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7013615" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Inhalation anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13319688" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Observations on the prophylaxis of experimental pulmonary anthrax in the monkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8486963" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Postexposure prophylaxis against experimental inhalation anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13736379" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11722269" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Death due to bioterrorism-related inhalational anthrax: report of 2 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16490913" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systematic review: a century of inhalational anthrax cases from 1900 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15288744" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical predictors of bioterrorism-related inhalational anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11747719" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11708591" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11851578" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fatal inhalational anthrax in a 94-year-old Connecticut woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14609791" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Gastrointestinal anthrax: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12737733" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Endemic gastrointestinal anthrax in 1960s Lebanon: clinical manifestations and surgical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12095428" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anthrax of the gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6696173" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12177364" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anthrax meningoencephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12177364" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Anthrax meningoencephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25139073" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Injectional anthrax - new presentation of an old disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12965942" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Accuracy of screening for inhalational anthrax after a bioterrorist attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3144920" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3144920" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12875989" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pathology and pathogenesis of bioterrorism-related inhalational anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578189" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26632963" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27025833" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Identifying Meningitis During an Anthrax Mass Casualty Incident: Systematic Review of Systemic Anthrax Since 1880.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Detecting Biothreat Agents: the Laboratory Response Network</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33939559" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Keeping up with the Bacillus cereus group: taxonomy through the genomics era and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32973690" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : You Can't B. cereus - A Review of Bacillus cereus Strains That Cause Anthrax-Like Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32973690" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : You Can't B. cereus - A Review of Bacillus cereus Strains That Cause Anthrax-Like Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36251561" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Welder's Anthrax: A Tale of 2 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34648482" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Notes from the Field: Fatal Anthrax Pneumonia in Welders and Other Metalworkers Caused by Bacillus cereus Group Bacteria Containing Anthrax Toxin Genes - U.S. Gulf Coast States, 1994-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36251548" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947-2019.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
